CTLA-4 mAb (9H10), InVivoPure+

ID: AK3607P+ Category:

The CTLA-4 mAb clone 9H10 antibody recognizes cytotoxic T lymphocyte antigen-4 (CTLA-4) also known as CD152.

This antibody is produced exclusively under serum-free conditions from hybridoma and purified with Protein-A or Protein-G affinity chromatography.

In stock

Delivery time: 2-5 days

From: 400,00 € Excl. VAT and delivery costs

Please contact us for larger quantities.

Endotoxin level ≤ 1 EU/mg

The CTLA-4 mAb clone 9H10 antibody recognizes cytotoxic T lymphocyte antigen-4 (CTLA-4) also
known as CD152. Antibody 9H10 has shown specific reactivity against CTLA-4 Ig but not CD4 lg,
as well as the ability to block CTLA-4 Ig by binding to B7 transfected cells. Staining of activated
T cells, but not freshly isolated T cells, is reported, as well as the ability to stain a CTLA-4
transfectant but not control transfectants. The CTLA-4 mAb (9H10) antibody has shown
effectiveness in reducing tumor growth and metastasis in preclinical models. These
characteristics make the 9H10 antibody a reliable tool for identifying and studying CTLA-4 in
various immunological contexts.

This antibody is produced exclusively under serum-free conditions from hybridoma and
purified with Protein-A or Protein-G affinity chromatography.

 

Product-ID: AK3607P+
Clone: 9H10
Immunogen: This antibody was raised by immunizing Syrian hamsters with heat-killed Staphylococcus A bacteria coated in CTLA-4.
Host: Syrian Hamster
Clonality: Monoclonal
Isotype: IgG
Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered
Concentration: ≥ 1.00 mg/mL
Purity: ≥ 95 % (CGE, reducing conditions)
≤ 5 % aggregates (analytical SEC)
Endotoxin: ≤ 1 EU/mg (LAL test)
Storage: 2 - 8 °C

 

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Additional information

Literature

[1] Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J
Exp Med. 1995 Aug 1;182(2):459-65. doi: 10.1084/jem.182.2.459. PMID: 7543139; PMCID: PMC2192127.
[2] Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition
of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34. PMID: 15701862.
Document

Product Information Sheet – AK3607P+
Notice

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Reviews

There are no reviews yet.

Be the first to review “CTLA-4 mAb (9H10), InVivoPure+”